Latest Treatment Innovations, Discoveries, and Best Practices to be Featured at 21st Annual Perspectives in Thoracic Oncology Conference
New York, New York (PRWEB) October 19, 2016 -- Chaired by Corey J. Langer, MD, FACP, Director of Thoracic Oncology at University of Pennsylvania’s Abramson Cancer Center, and organized by Imedex, the 21st Annual Perspectives in Thoracic Oncology will be an unparalleled educational conference in that it will be the first gathering of US-based experts in lung cancer after the close of the 2016 ESMO Congress. Held on November 18-19 in New York City, the conference offers 2 full days of interactive sessions which allows optimal time for more detailed coverage and interactivity than many of the traditional 1-day lung cancer meetings.
According to Dr. Langer who has served as conference chair for the past 11 consecutive years, the conference is a long-standing premier educational event highlighting best practice and exciting innovations across all aspects of lung cancer care. “Whether the clinician is a community-based oncologist or practices in an academic center, this conference will deliver scientifically rigorous information in a clinically-relevant context by highly respected lung cancer experts,” said Dr. Langer.
As expected, much of the excitement at this year’s conference will center around immunotherapy, in particular, the use of checkpoint inhibitors for NSCLC; over 7 sessions and a half a days content will be devoted to the topic. Other targeted therapies that are furthering the promise of personalized medicine will also be featured. Importantly, alongside the presentations focused on primary treatment, the conference will also include provocative discussions on lung cancer screening, supportive care topics such as managing cachexia, and shared decision making strategies for end-of-life decisions.
Along with interactive presentations, the conference will feature debate-style sessions in which two experts posit arguments highlighting two opposing perspectives of a clinical issue. There will also be panel discussions in which leading faculty share their own evidence-based clinical opinions.
As in the past, the meeting will be certified and organized by Imedex, an industry leader in providing oncology CME programs in a live conference setting and online. Imedex is pleased to once again be partnering with the conference chair and faculty to provide this educational program to the thoracic oncology community. To register or for more information, please visit http://www.perspectivesinthoraciccancer.com
About Imedex®
Imedex is the industry leader in developing and delivering independent, accredited health care education. Our programs, specializing in oncology, hematology, and gastroenterology, are provided through live events around the world, as well as effective online educational opportunities for on-the-go healthcare providers.
With high-quality scientific programming translating the latest research into clinically-relevant information, our activities address the needs of healthcare professionals inundated by information through exceptional organization and outstanding educational value, with a proven sustained impact on patient care.
Since 2001, our global footprint has provided over 50,000 E-learning experiences annually, and our live conferences have interfaced with more than 100,000 attendees from over 100 countries, including the United States, Europe and Asia.
At Imedex, education is the best medicine®. For more information on Imedex, visit us online at http://www.imedex.com or on our e-learning center at http://elc.imedex.com.
Upcoming live events include:
Advances in Inflammatory Bowel Diseases, Crohn’s & Colitis Foundation of America’s Clinical & Research Conference
December 8-10, 2016
Orlando, Florida
ESMO 19th World Congress on Gastrointestinal Cancer
28 June - 1 July 2017
Barcelona, Spain
Tradd Sanderson, Imedex, http://www.imedex.com, +1 4047841276, [email protected]
Share this article